Hematology Billing 2026: Infusion Codes, Anemia Management & Payer Audit Exposure

Hematology practices administering infusions for blood disorders, anemia, clotting disorders, and hematologic malignancies see denial rates of 18% to 28% — significantly higher than most outpatient specialties. The gap between what's administered and what's collected routinely runs $60,000 to $180,000 per year for mid-sized practices. Most of that gap comes from infusion code sequencing errors, drug billing documentation failures, and missed opportunities to bill separately billable services on infusion days.

Infusion CPT Codes for Hematology: Chemo vs. Non-Chemo Distinction

The most foundational billing decision in hematology infusion is whether the drug being administered classifies as a chemotherapy agent under Medicare's definition. This isn't just a clinical question — it's a billing question with direct reimbursement implications. Chemo infusion codes reimburse differently than therapeutic drug infusion codes, and using the wrong family leads to underpayment or denials.

The sequencing rule is the most common source of billing errors. When multiple infusions happen on the same day, the "primary" service is the one with the highest CPT hierarchy — chemotherapy infusion, then therapeutic drug infusion, then hydration. The additional services are billed as add-on codes. Getting this order wrong generates bundling denials that look like payment but aren't — the claim pays at the wrong rate.

Drug Billing in Hematology: HCPCS J-Codes and Documentation Requirements

In hematology, drug billing often represents more revenue than the infusion services themselves. ESAs, IVIG, iron sucrose, rituximab, and specialty biologics can run $500 to $15,000 per infusion encounter. Billing them correctly — right J-code, right units, right documentation — is where practices either capture or lose that revenue.

Every hematology practice should have a clean J-code reference for their most frequently administered agents. Here are the key ones:

ESA Billing for Anemia: The Hemoglobin Threshold Rules

Erythropoiesis-stimulating agents represent one of the highest-value — and highest-scrutiny — drug categories in hematology billing. Medicare has strict hemoglobin threshold requirements for ESA coverage, and violations aren't just claim denials. They're OIG enforcement targets.

For Medicare coverage of ESAs in non-dialysis patients with anemia of chronic kidney disease, the hemoglobin must be documented below 10 g/dL before ESA initiation. Once started, the ESA must be dose-reduced or held if hemoglobin reaches 10 g/dL, and must be stopped if it exceeds 12 g/dL. These are bright lines — not clinical guidelines with wiggle room.

Prior Authorization for High-Cost Hematology Drugs

Romiplostim (Nplate) for ITP, eltrombopag (Promacta), luspatercept (Reblozyl) for MDS-related anemia, and several other specialty hematology agents require prior authorization from virtually every commercial payer. The auth requirements are diagnosis-specific and, in many cases, dose-specific.

For romiplostim, commercial payer auth typically requires:

• ITP diagnosis with documented platelet counts below 30,000/μL
• Documentation that the patient has failed at least one prior treatment (steroids, IVIG, or splenectomy where applicable)
• Hematologist attestation that the drug is being used per FDA-approved indications
• Baseline platelet count from within 30 days

Auth expirations are a persistent revenue problem in hematology more than almost any other specialty, because patients are on these agents long-term. A patient on romiplostim for 18 months has had their auth renewed — or failed to have it renewed — multiple times. Each lapse in auth renewal means claims going out without coverage. Practices need a tickler system that flags renewals 30 days before expiration, not when the denial arrives.

Common Hematology Infusion Billing Denials

Denial patterns in hematology infusion are consistent enough to build a prevention workflow around. The top three drivers account for nearly 70% of denied dollars.

Infusion time documentation insufficient (30% of denials): The infusion code billed doesn't match the documented infusion time. 96413 covers the first hour of chemo infusion. If the nursing note shows start and stop times of 9:05 AM to 9:48 AM, you don't have a full hour documented — and the payer will deny or downcode. Practices need infusion logs that capture start time, stop time, and any interruptions. Nursing documentation has to match what's on the claim.

Drug units billed don't match the administration record (25% of denials): This is especially common with weight-based dosing. The dose ordered is 375 mg/m² of rituximab, the patient's BSA is 1.8, the dose administered is 675 mg, which is 6.75 units of J9312 (per 100 mg). If the claim goes out as 7 units instead of rounding down per administered dose, payers audit this. The administration record — including the exact amount drawn and infused — needs to tie to the HCPCS units on the claim.

Modifier 25 missing on E/M billed with infusion (15% of denials): When the physician sees the patient for a decision-making visit on the same day as an infusion, the E/M needs modifier 25. Without it, the payer bundles the E/M into the infusion code and pays only the infusion. The E/M documentation also needs to reflect independent medical decision-making beyond just "patient here for scheduled infusion."

OIG Work Plan: Hematology Audit Risk Areas

OIG has flagged several hematology-specific billing patterns for active review. The most significant are ESA administration without threshold documentation, billing for longer infusion time than documented, and concurrent infusion unbundling that violates the sequencing rules.

RAC auditors targeting hematology/oncology infusion practices typically pull 3 years of claims and sample across infusion days. A practice billing 1,200 infusion encounters per year with a 20% error rate on infusion time documentation — which is common — faces potential recoupment on 720 encounters over 36 months. At an average infusion service revenue of $280 per encounter, that's $201,600 in recoupment exposure before interest and penalties.

Defensive documentation that holds up under audit: infusion logs in the chart that show start/stop times, a claim scrubbing workflow that compares billed hours to documented hours before submission, and a standing audit of J-code units against pharmacy dispense records quarterly. None of these are complex. They're workflow issues, not clinical ones.